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Background: Despite the enthusiastic midterm results of the LEADERS trial, few is known about long term efficacy and safety of the Biomatrix 
stent (BES) which comprises a stainless steel platform with a sirolimus-analogous as anti-proliferative agent delivered in a biodegradable abluminal 
polymer. The present report represents the longest-available serial invasive assessment of this novel technology.
Methods: Between November 2003 and March 2004, 32 pts with single de novo lesions were prospectively enrolled in a randomized first-in-man 
evaluation of BES. All eligible pts that did not experience major adverse cardiac events during the FU period were contacted and re-consented for 
6 years angiographic/intravascular ultrasound (IVUS) evaluation. The main goal was to assess the variation of intimal hyperplasia (IH) volume and 
angiographic late-loss, between 6-month and 6-years FU.
Results: 14 where re-consented to participate in this study. Mean cohort age was 61 years and 29% of the patients had DM. Angiographic late 
loss was 0.20 mm at 6-month and 0.29 mm at 6-years FU (p=0.82). Neointima hyperplasia volume was 1.2 mm3 vs. 4.9 mm3 (p=0.054), while % 
neointima obstruction was 0.7% vs. 3.8% (p=0.06), at 6-month and 6 years respectively. Figure shows the distribution of IH. There were no cases of 
late acquired ISA.
Conclusions: In this small single center experience, BES with biodegradable polymer demonstrated favorable very long term angiographic and 
IVUS results, with maintenance of the initial findings. 
